The WHO's 13-Country Study on Cell Phones and Brain Tumors: What Interphone Actually Found

The Interphone study is frequently cited in mainstream coverage of EMF health risks as evidence that cell phones are safe. This characterization is selective. The Interphone study — a massive, multi-country case-control study organized by the WHO's International Agency for Research on Cancer (IARC) and conducted in 13 countries between 2000 and 2004 — found a statistically significant increased risk of glioma in the heaviest users of mobile phones. The headline finding was obscured by methodological choices that, if anything, biased the study toward finding no effect. Understanding what Interphone actually found, and why its design limited its ability to detect long-term risk, is essential for interpreting the EMF health evidence base.

Study Overview

The Interphone study recruited 2,708 glioma cases, 2,409 meningioma cases, and matched controls from 13 countries (Australia, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Sweden, and the United Kingdom). It was the largest epidemiological study of mobile phone use and brain tumors ever conducted, and its organization by IARC gave it significant institutional authority.

The primary question was whether mobile phone use is associated with increased risk of glioma (malignant brain tumor) or meningioma (typically benign brain tumor). The study used a retrospective case-control design: brain tumor patients were interviewed about their mobile phone use history, and their responses were compared with controls from the general population.

Results were published in the International Journal of Epidemiology in 2010, nearly a decade after data collection began.

What Interphone Found

The study's summary statistics, widely reported in media coverage, showed an overall odds ratio for glioma in mobile phone users below 1.0 — a result that appears protective (lower risk in users than non-users). This finding drove the headline narrative that the study found no increased risk.

But the aggregate statistic obscures the most important finding in the data. When the researchers looked specifically at the top decile of users — those in the highest 10% of cumulative call time — they found a statistically significant 40% increased odds of glioma (odds ratio 1.40, 95% CI 1.03–1.89). These were users with more than 1,640 cumulative hours of mobile phone use over their lifetime.

The same group showed a nonsignificant trend toward increased meningioma risk, and the spatial distribution of tumors showed the same ipsilateral pattern documented in the Hardell studies: tumors were more likely to occur on the same side of the head as the phone was typically used.

The dose-response relationship — higher use associated with higher risk — is the epidemiological signature of a causal effect. The Interphone data show this pattern among the heaviest users while the overall result is muddied by methodological problems that make the lower-use categories appear protective.

Methodological Problems That Biased Toward the Null

Critics of the Interphone study, including Hardell and other independent researchers, identified several design choices that would bias the study toward finding no effect or artificially protective effects:

Short latency period: The study's follow-up period was insufficient to detect radiation-induced tumors. Glioma from radiation exposure typically has a latency period of 10+ years. Many Interphone participants had used mobile phones for fewer than 10 years, meaning tumors induced by their early phone use may not yet have appeared at the time of data collection.

Exclusion of the most affected groups: The Interphone protocol excluded participants over 59 years old (a high-risk cancer age group), rural populations (where call times may be higher due to worse signal), and people who died before enrollment (fatal tumors). These exclusions selectively removed high-exposure, high-risk individuals from the study.

The healthy user effect: Early mobile phone adopters in the study period tended to be business professionals and higher-income individuals who may have had better health outcomes than the general population for non-EMF reasons. This could produce a spurious protective effect in lower-use categories.

Industry involvement in design: The telecommunications industry provided partial funding for the Interphone study and had a seat at the design table. Hardell and others documented that several design choices that limit the study's sensitivity to detecting effects were made during this industry-involved design phase.

Control group misclassification: Many of the controls in the Interphone study were themselves mobile phone users, making it a study of heavy users vs. regular users rather than users vs. non-users. This compresses the exposure contrast and makes it harder to detect a dose-response relationship.

How the IARC Used Interphone

Despite its limitations, Interphone was one of the primary evidence sources for the IARC's 2011 working group that classified radiofrequency electromagnetic fields as a Group 2B possible carcinogen. The IARC noted the heavy-user glioma finding as contributing to the classification, while acknowledging the study's methodological limitations.

The Interphone data, read without the spin of the headline summary statistic, is consistent with the Hardell findings: heavy, long-term users show increased glioma risk. The difference is that the Hardell studies, with longer follow-up and no industry funding involvement, found stronger associations and were better positioned to detect latency-dependent effects.

What Interphone Means for the EMF Evidence Base

The Interphone study is important evidence in the EMF health debate, but not for the reason it is usually cited. It is not evidence that mobile phones are safe. It is evidence that even a methodologically imperfect, industry-influenced, insufficiently long-latency study of 5,000+ brain tumor cases found a significant increased risk in the heaviest users.

Read alongside the Hardell case-control series (which found stronger effects with longer follow-up and no industry involvement), the NTP and Ramazzini animal studies (which found the same tumor types at regulatory-range exposures), and the BioInitiative synthesis of 1,800+ biological effects studies, Interphone fits a coherent pattern: real biological effects, attenuated and obscured by study design choices that favor the null hypothesis.

What This Means for EMF Exposure and Protection

The Interphone study's own data show that the heaviest cell phone users — those with more than 1,640 hours of cumulative use — face a 40% higher odds of glioma. This is not a finding buried in alternative literature. It is in the primary study publication, in the International Journal of Epidemiology, accessible to anyone who reads past the summary statistic.

For people thinking about cell phone radiation and EMF protection, the Interphone data identifies cumulative exposure as the key variable: it is not any single call but the accumulation of hours of proximity to a radiating device that the data associates with increased risk. This has direct implications for everyday practices — speaker phone distance, duration of direct contact, and the use of any intervention that reduces the biological activity of proximity-range cell phone radiation.

Approaches to EMF protection that address the structural properties of emitted electromagnetic radiation — structural field modulation and modification of field coherence properties — are relevant to the cumulative exposure concern the Interphone data documents. The goal is not to block the signal but to change the interaction profile of radiofrequency radiation as it passes through biological tissue — addressing the non-thermal mechanism the existing research literature consistently identifies as the source of biological effects.

The WHO's 13-Country Study on Cell Phones and Brain Tumors: What Interphone Actually Found